Phenylalanine

Phenylalanine is an aromatic alpha-amino acid and one of the proteinogenic amino acids used by all living things to build proteins ^[1]. It is classified as an essential amino acid because humans and other mammals cannot synthesize it and must take it in through the diet. It exists in three related forms: L-phenylalanine, the biologically active form found in proteins; D-phenylalanine, a synthetic mirror-image form; and DL-phenylalanine, a racemic mixture of the two that is sold as a supplement ^[1].

Beyond its role as a protein building block, phenylalanine is a metabolic starting point for a number of important molecules. The body converts it into tyrosine, which in turn is used to make the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine, as well as thyroid hormones and the pigment melanin ^[1]. Dietary phenylalanine comes mainly from protein-rich foods such as meat, fish, eggs, dairy products, soybeans, and nuts, and it is also released during digestion of the sweetener aspartame, which is built in part from phenylalanine ^[3]. Nutritional requirements for phenylalanine are usually considered together with those for tyrosine, since the two are metabolically linked ^[3].

The amino acid is central to phenylketonuria (PKU), an inherited disorder caused by deficiency of the enzyme phenylalanine hydroxylase ^[2]. In this condition phenylalanine cannot be efficiently converted to tyrosine, so it accumulates in the blood, and if the disorder is not treated from early infancy the excess interferes with brain development and causes intellectual disability ^[2]. Because of this, newborns are screened for PKU, and affected individuals follow a lifelong diet that restricts phenylalanine and supplies a special phenylalanine-free protein substitute; some patients also benefit from the cofactor tetrahydrobiopterin ^[2][4]. It is for people with PKU that products sweetened with aspartame carry a statement that they contain phenylalanine, and women with PKU require especially careful control during pregnancy because high levels can harm the developing fetus ^[2].

The synthetic and racemic forms are sometimes marketed as dietary supplements; DL-phenylalanine, in particular, has been promoted for pain and mood, although the supporting evidence is limited ^[1]. Industrially, L-phenylalanine is produced on a large scale, notably for the manufacture of aspartame ^[3].

One contraindication outranks everything else on this page. In phenylketonuria, phenylalanine hydroxylase is deficient or absent, phenylalanine accumulates, and the accumulation is directly harmful to the brain; effects on brain function are measurable in adults with the condition, not only in children ^[7][8]. Anyone with PKU, or with a variant of hyperphenylalaninaemia, must not supplement phenylalanine. This is the reason aspartame carries a PKU warning, and the same logic applies with far more force to a concentrated supplement.

Beyond that, phenylalanine interacts with drugs in a way that matters. It is a catecholamine precursor, so combining it with a monoamine oxidase inhibitor is a route to hypertensive effects and should not be done without a prescriber's involvement; the same caution applies to selegiline and to Parkinson's regimens where catecholamine handling is already being manipulated pharmacologically. Anyone taking levodopa should not add it casually, since both compete for the same amino acid transport into the brain.

Ordinary supplemental use in healthy adults is generally well tolerated, with the reported problems being mild: nausea, heartburn, headache, and restlessness or insomnia if taken late, which follows from the pathway it feeds. Pregnancy is a reason to defer to a clinician rather than self-supplement, given how tightly maternal phenylalanine is managed in PKU care. There is no long-term safety data at high supplemental doses ^[20]. Liver and kidney impairment change phenylalanine and tyrosine handling and are further reasons to involve a clinician ^[18][17].

Phenylalanine can be decarboxylated to the biogenic amine phenylethylamine, which acts similarly to tyramine. In the presence of monoamine oxidase (MAO) inhibitors, elevated dietary or supplemental phenylalanine may precipitate a hypertensive crisis through accumulation of biogenic amines. In contrast, selective MAO-B inhibitors such as selegiline and rasagiline at therapeutic doses (5 to 10 mg daily) do not significantly potentiate tyramine-induced hypertension and maintain reasonable dietary flexibility, though higher supratherapeutic doses may lose selectivity for MAO-B. ^{[5] [6]}

Checking a whole stack? Run it through interactions + stacks.

Phenylalanine was identified as one of the essential amino acids during the classical nutritional work of the early twentieth century, and its early scientific significance was pathological rather than supplemental. Phenylketonuria, described in 1934, gave phenylalanine an outsized place in medicine: it became the first inherited metabolic disorder shown to be manageable by diet, and newborn screening for it became one of the earliest population screening programmes anywhere ^[15]. A deficiency syndrome from over-restriction was described in turn, which established that the amino acid has a floor as well as a ceiling ^[16].

The therapeutic uses came later and from different directions. L-phenylalanine with ultraviolet light entered dermatological practice for vitiligo in the 1980s and has persisted in treatment guidelines and reviews since ^[13][12]. D-phenylalanine and the DLPA mixture were promoted from the 1970s onward on an enkephalinase-inhibition rationale for chronic pain, and that proposal has not accumulated the trial evidence that would settle it.

Modern interest runs along two tracks. Metabolic research continues on how inflammation disrupts phenylalanine and tryptophan handling in depression ^[14], and clinical PKU research continues on cofactor therapy and on quantifying the cognitive cost of raised phenylalanine in adults ^[19][7].

Phenylalanine is usually encountered as the raw material for dopamine, and the promise attached to that framing runs well ahead of what the trials show. Precursor loading is an appealing idea because the pathway is real and easy to draw; the part that does not appear in the marketing is that tyrosine hydroxylase is rate-limiting and feedback-inhibited, so more substrate does not reliably produce more transmitter.

Among people who use it deliberately, DLPA has the strongest word-of-mouth reputation, mostly for mood and for chronic pain, on the basis of the enkephalinase rationale. That reputation is older than its evidence and has not been closed out by good trials in either direction.

The use with the most respectable standing is the one fewest readers arrive looking for: L-phenylalanine with light therapy in vitiligo, which appears in dermatological reviews as a legitimately supported adjunct rather than a fringe option ^[9][10][11].

Its other public identity is as a warning label. The PKU caution printed on every aspartame-containing product is the reason most people have seen the word at all, and it is a useful association to keep, because the same contraindication applies with far greater force to a supplement.